“A combo of Bristol Myers’ LAG-3 inhibitor relatlimab and PD-1...

“A combo of Bristol Myers’ LAG-3 inhibitor relatlimab and PD-1 blocker Opdivo posted a progression-free survival of 10.12 months in patients with metastatic or unresectable melanoma compared with 4.63 months for patients on Opdivo alone, according to data from the Phase II/III RELATIVITY-047 study set to be presented at ASCO in June.”

“On top of adding a novel molecule into the fold, an approval would crack open a whole new world of combo potential for Opdivo, Bristol Myers’ third-bestselling drug and a clear No. 2 in terms of PD-1 sales behind Merck’s behemoth Keytruda. Opdivo cleared $1.72 billion in sales in Q1.”

https://endpts.com/asco21-bristol-m...udy-for-lag-3-pathway-setting-up-a-us-filing/